Composition
Each scored film coated tablet contains:
Olanzapine .................................. 10 mg
Inactive ingredients: Microcrystalline Cellulose, lactose, plasdone XL, magnesium stearate, hydroxypropyl cellulose LF, hydroxypropyl methyl cellulose 2910, polyethylene glycol 6000, titanium dioxide.

Therapeutic Indications
Adults:
OLAZINE is indicated for the treatment of schizophrenia.
OLAZINE is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.
OLAZINE is indicated for the treatment of moderate to severe manic episode.
In patients whose manic episode has responded to OLAZINE treatment, OLAZINE is indicated for the prevention of recurrence in patients with bipolar disorder.

Dosage and Administration
Adults:
Schizophrenia:
The recommended starting dose for OLAZINE is 10 mg/day.
Manic episode:
The starting dose for OLAZINE is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy.
Preventing recurrence in bipolar disorder:
The recommended starting dose is 10 mg/day.
For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, OLAZINE treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.
During treatment for schizophrenia, manic episode, and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20 mg/day. An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours.
OLAZINE can be given without regard for meals, as absorption is not affected by food.
Gradual tapering of the dose should be considered when discontinuing OLAZINE.
Paediatric population:
OLAZINE is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy of olanzapine.
A greater magnitude of weight gain, lipid and prolactin alterations has been reported in short-term studies of adolescent patients than in studies of adult patients.
Elderly:
A lower starting dose (5 mg/day) is not routinely indicated but should be considered for those 65 years and over when clinical factors warrant.
Renal and/or hepatic impairment:
A lower starting dose (5 mg) should be considered for such patients.
In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh class A or B), the starting dose should be 5 mg and only increased with caution.
Gender:
The starting dose and dose range need not be routinely altered for female patients relative to male patients.
Smokers:
The starting dose and dose range need not be routinely altered for non-smokers relative to smokers.
When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the starting dose. Dose escalation, when indicated, should be conservative in such patients.
In cases where dose increments of 2.5 mg are considered necessary, OLAZINE coated tablets should be used